Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.82 and traded as low as $3.48. Cryo-Cell International shares last traded at $3.64, with a volume of 7,996 shares changing hands.

Cryo-Cell International Stock Performance

The firm has a fifty day simple moving average of $3.31 and a 200-day simple moving average of $3.82. The stock has a market cap of $29.34 million, a price-to-earnings ratio of -11.74 and a beta of 0.54.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its earnings results on Friday, February 27th. The company reported ($0.47) EPS for the quarter. The firm had revenue of $7.84 million during the quarter.

Institutional Trading of Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International as of its most recent SEC filing. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.